Fulgent Genetics Inc (NAS:FLGT)
$ 22.3585 -0.1415 (-0.63%) Market Cap: 669.06 Mil Enterprise Value: 379.95 Mil PE Ratio: 0 PB Ratio: 0.59 GF Score: 74/100

Q3 2022 Fulgent Genetics Inc Earnings Call Transcript

Nov 07, 2022 / 09:30PM GMT
Release Date Price: $35.52 (-6.48%)
Operator

Hello, and welcome to the Fulgent Genetics Q3 2022 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to your host, Melanie Solomon, Investor Relations. Please go ahead.

Melanie Solomon
The Blueshirt Group, LLC - MD

Good afternoon, and welcome to the Fulgent Genetics third quarter 2022 financial results conference call. Today, we will also be discussing the acquisition of Fulgent Pharma announced after the markets closed in a separate press release. On the call are Ming Hsieh, Chief Executive Officer of Fulgent Genetics; Paul Kim, Chief Financial Officer of Fulgent Genetics; Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics; Lawrence Weiss, Chief Medical Officer of Fulgent Genetics; and Dr. Ray Yin, President and Chief Scientific Officer of Fulgent Pharma.

The company's press release discussing these 2 announcements are available on the Investor Relations section of our website, fulgentgenetics.com. The webcast portion of this call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot